^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Adenocarcinoma

    Related cancers:
    12h
    IGNITE: Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, University of Pennsylvania | Trial completion date: Aug 2027 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Imprime PGG (odetiglucan) • mitazalimab (ADC-1013)
    14h
    Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (clinicaltrials.gov)
    P2, N=46, Completed, Yale University | Active, not recruiting --> Completed
    Trial completion
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    18h
    Characterisation of early-onset pancreatic adenocarcinoma molecular profile compared to average-onset pancreatic adenocarcinoma (CARAPAC): A systematic review and a meta-analysis. (PubMed, Pancreatology)
    EOPA is enriched in KRAS wild-type tumours. This profile may offer alternative therapeutic opportunities, including RNA-based fusion detection, inclusion in targeted therapy trials, and suggest alternative oncogenic pathways for a proportion of this subpopulation. Standardised definitions, consistent molecular reporting, and exploration of age-specific risk factors are critical to improve understanding and management of EOPA.
    Retrospective data • Journal • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4)
    |
    KRAS mutation • BRCA2 mutation • KRAS wild-type • RAS wild-type
    22h
    A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer (clinicaltrials.gov)
    P3, N=614, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • setidegrasib (ASP3082) • Onivyde (nanoliposomal irinotecan) • levoleucovorin calcium
    1d
    FAZA PET/MRI Pancreas (clinicaltrials.gov)
    P=N/A, N=20, Active, not recruiting, University Health Network, Toronto | Trial completion date: Mar 2025 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    1d
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, I-Mab Biopharma US Limited | N=168 --> 330 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    Opdivo (nivolumab) • Imfinzi (durvalumab) • givastomig (TJ-CD4B)
    3d
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    4d
    Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=3, Terminated, Mayo Clinic | N=54 --> 3 | Trial completion date: Jul 2027 --> Nov 2025 | Recruiting --> Terminated | Trial primary completion date: Jul 2026 --> Nov 2025; Low/slow accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    5d
    Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) (clinicaltrials.gov)
    P1/2, N=24, Recruiting, University of Maryland, Baltimore | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel
    5d
    Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer (clinicaltrials.gov)
    P3, N=58, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=120 --> 58
    Enrollment closed • Enrollment change
    8d
    NEO-Nal- IRI: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, University of Florida | Trial completion date: Feb 2026 --> Dec 2026
    Trial completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • CA 19-9 (Cancer antigen 19-9)
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)